ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1609175

This article is part of the Research TopicHarnessing Molecular Insights for Enhanced Drug Sensitivity and Immunotherapy in CancerView all 35 articles

Bioinformatics-based analysis of nicotinamide adenine dinucleotide metabolism genes to predict immune status and prognosis for head and neck squamous cell carcinoma patients

Provisionally accepted
  • 1First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
  • 2The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, China

The final, formatted version of the article will be published soon.

Patients suffering from head and neck squamous cell carcinoma (HNSCC) have a high recurrence rate and poor prognosis. Nicotinamide adenine dinucleotide (NAD + ) is crucial in the progression of the tumor. Currently, the specific role of NAD + in HNSCC remains elusive.Methods: First, weighted gene co-expression network analysis (WGCNA) was utilized to screen gene modules linked to NAD + metabolism-related genes (NMRGs), and the expression profiles obtained were taken as intersections with differentially expressed genes (DEGs) between HNSCC and control samples. The genes were then further compressed and risk modeled using LASSO and stepwise regression analyses. Then the gene mutation landscapes of different risk subgroups of HNSCC were analyzed using MuTect 2 software. Differences in biological function and immune infiltration analyses between different subgroups were explored. In addition, scratch and transwell assays were carried out to explore the role of PSME1 in HNSCC cells.Here, we screened two specific modules with the strongest relation to HNSCC by WGCNA and subsequently took the intersection of 6160 DEGs with the module genes, obtaining a total of 359 intersected genes. Six (ICOS, PSME1, SERPINA1, SH3KBP1, SP100 and ZAP70) characterized genes linked to HNSCC prognosis were selected for risk modeling. We categorized patients by the risk scores into high-and low-risk groups. Overall survival of patients in the low-risk group was significantly better than those in the high-risk group. Compared to the low-risk group, the mutation rates of FAT1, TP53, TTN genes were higher in the high-risk group, with a coexistence between the mutated genes. The expression of the characterized genes showed a positive association with the level immune cell infiltration, for example, activated CD8 T cells. The enrichment analysis demonstrated that differential genes in the high-risk HNSCC group were significantly enriched in the ribosome and other pathways, while the differential genes in the low-risk group were mainly involved in arachidonic acid metabolism and other pathways. Further in vitro assay revealed that downregulated PSME1 attenuated the migratory and invasive abilities of FaDu cells.Conclusions: The current work provided theoretical references for future study on potential biomarkers of prognosis and immune infiltration in patients suffering from HNSCC.

Keywords: WGCNA analysis, Prognostic modeling, Head and neck squamous cell carcinoma, gene mutation, Immune infiltration

Received: 10 Apr 2025; Accepted: 10 Jun 2025.

Copyright: © 2025 Guan, Gu and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lian Zheng, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.